METABOLISM AND ACTION OF PURINE NUCLEOSIDE ANALOGS

被引:140
作者
PLUNKETT, W
SAUNDERS, PP
机构
[1] Department of Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston
关键词
D O I
10.1016/0163-7258(91)90057-S
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent investigations have identified many new purine nucleoside analogs that act as antimetabolites. This article focuses on the metabolism and mechanisms of action of tiazofurin, 3-deazaguanosine, neplanocin A, arabinosyladenine in combination with inhibitors of adenosine deaminase, arabinosyl-2-fluoroadenine, and 2-chloro-2'-deoxyadenosine, drugs that are either currently being evaluated in clinical trials or are close to that stage. The diverse metabolic requirements for activation, unique mechanisms of action, and differential biological activities of these compounds are characterized and evaluated for prospective therapeutic application.
引用
收藏
页码:239 / 268
页数:30
相关论文
共 345 条
[1]   THE MECHANISM OF INACTIVATION OF S-ADENOSYLHOMOCYSTEINASE BY 2'-DEOXYADENOSINE [J].
ABELES, RH ;
TASHJIAN, AH ;
FISH, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1980, 95 (02) :612-617
[2]   ADENOSINE-ANALOGS AND HUMAN PLATELETS - EFFECTS ON NUCLEOTIDE POOLS AND AGGREGATION PHENOMENON [J].
AGARWAL, KC ;
PARKS, RE .
BIOCHEMICAL PHARMACOLOGY, 1975, 24 (24) :2239-2248
[3]   INHIBITORS OF ADENOSINE-DEAMINASE [J].
AGARWAL, RP .
PHARMACOLOGY & THERAPEUTICS, 1982, 17 (03) :399-429
[4]  
AGARWAL RP, 1982, CANCER RES, V42, P3884
[5]   STUDIES ON THE MECHANISM OF ACTION OF 2-BETA-D-RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE .5. FACTORS GOVERNING THE RESPONSE OF MURINE TUMORS TO TIAZOFURIN [J].
AHLUWALIA, GS ;
JAYARAM, HN ;
PLOWMAN, JP ;
COONEY, DA ;
JOHNS, DG .
BIOCHEMICAL PHARMACOLOGY, 1984, 33 (08) :1195-1203
[6]   STUDIES ON THE MECHANISM OF ACTION OF TIAZOFURIN (2-BETA-D-RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE) .6. BIOCHEMICAL AND PHARMACOLOGICAL STUDIES ON THE DEGRADATION OF THIAZOLE-4-CARBOXAMIDE ADENINE-DINUCLEOTIDE (TAD) [J].
AHLUWALIA, GS ;
COONEY, DA ;
MARQUEZ, VE ;
JAYARAM, HN ;
JOHNS, DG .
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (21) :3783-3790
[7]  
ARDALAN B, 1986, P AM ASSOC CANC RES, V27, P173
[8]  
ARENDS MJ, 1990, AM J PATHOL, V136, P593
[9]  
ARNOLD ST, 1984, DRUG METAB DISPOS, V12, P165
[10]  
AVERY TL, 1989, CANCER RES, V49, P4972